Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: Yahoo! Finance
US$0.34 loss per share (down from US$1.07 profit in 3Q 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 65%. Earnings per share (EPS) also surpassed analyst estimates by 56%. Looking ahead, revenue is expected to decline by 81% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 21%. Performance of the American Biotechs industry. The company's shares are up 7.8% from a week ago. Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Entrada Therapeutics (1 is a bit concerning) you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased me
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $25.00 to $28.00. They now have an "outperform" rating on the stock.MarketBeat
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle SocietyGlobeNewswire
TRDA
Earnings
- 11/5/24 - Beat
TRDA
Sec Filings
- 11/12/24 - Form 144
- 11/12/24 - Form 144
- 11/6/24 - Form 4
- TRDA's page on the SEC website